Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, Paszat LF.

J Clin Oncol. 2009 Jul 20;27(21):3452-8. doi: 10.1200/JCO.2008.20.0923.

PMID:
19506162
2.

Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.

Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L.

J Urol. 2010 Sep;184(3):918-23. doi: 10.1016/j.juro.2010.04.068.

PMID:
20643458
3.

The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.

Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, Saad F, Graefen M, Briganti A, Montorsi F, Karakiewicz PI.

BJU Int. 2014 Dec;114(6b):E82-9. doi: 10.1111/bju.12732.

4.

Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.

Wang A, Obertová Z, Brown C, Karunasinghe N, Bishop K, Ferguson L, Lawrenson R.

BMC Cancer. 2015 Nov 2;15:837. doi: 10.1186/s12885-015-1843-3.

5.

Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.

Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL.

BJU Int. 2013 May;111(5):745-52. doi: 10.1111/j.1464-410X.2012.11758.x.

6.

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Keating NL, O'Malley AJ, Smith MR.

J Clin Oncol. 2006 Sep 20;24(27):4448-56.

PMID:
16983113
7.

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.

Taylor LG, Canfield SE, Du XL.

Cancer. 2009 Jun 1;115(11):2388-99. doi: 10.1002/cncr.24283. Review.

8.

Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.

Martín-Merino E, Johansson S, Morris T, García Rodríguez LA.

Drug Saf. 2011 Nov 1;34(11):1061-77. doi: 10.2165/11594540-000000000-00000.

PMID:
21981434
9.

Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.

Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D'Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.

BJU Int. 2015 Sep;116(3):358-65. doi: 10.1111/bju.12905.

10.

Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer.

Teoh JY, Chiu PK, Chan SY, Poon DM, Cheung HY, Hou SS, Ng CF.

Aging Male. 2015;18(3):180-5. doi: 10.3109/13685538.2015.1046043.

PMID:
26004988
11.

Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.

Sun M, Choueiri TK, Hamnvik OP, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.

JAMA Oncol. 2016 Apr;2(4):500-7. doi: 10.1001/jamaoncol.2015.4917.

PMID:
26720632
12.

Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

Eur Urol. 2013 Jul;64(1):159-66. doi: 10.1016/j.eururo.2012.04.035.

13.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24.

14.

Androgen deprivation in veterans with prostate cancer: implications for skeletal health.

Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.

Ann Pharmacother. 2006 Dec;40(12):2107-14.

PMID:
17132807
15.

Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.

Wu CT, Yang YH, Chen PC, Chen MF, Chen WC.

Osteoporos Int. 2015 Sep;26(9):2281-90. doi: 10.1007/s00198-015-3135-9.

PMID:
25990353
16.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

J Natl Cancer Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Erratum in: J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23.

17.

Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.

O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M.

J Clin Oncol. 2015 Apr 10;33(11):1243-51. doi: 10.1200/JCO.2014.59.1792.

PMID:
25732167
18.

Fracture risk in androgen deprivation therapy: a Canadian population based analysis.

Lau YK, Lee E, Prior HJ, Lix LM, Metge CJ, Leslie WD.

Can J Urol. 2009 Dec;16(6):4908-14.

PMID:
20003666
19.

Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.

Tsai HT, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Smith MR, Potosky AL.

J Urol. 2015 Jun;193(6):1956-62. doi: 10.1016/j.juro.2014.12.027.

20.

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK.

JAMA. 2011 Dec 7;306(21):2359-66. doi: 10.1001/jama.2011.1745.

PMID:
22147380
Items per page

Supplemental Content

Support Center